Cadila Pharmaceuticals has just announced the entry of its new drug for lung cancer management. This is seen as an important development in the treatment of lung cancer.
The drug, Mycidac-C, can be used for victims suffering from a cancer sub-type - non-small cell lung cancer.
10 injections come at a price of Rs.4000 and the total expenditure for therapy to patients is estimated at Rs 40,000.
Cadila CMD Dr Rajiv Modi said, "Our drug is a significant breakthrough in the management of squamous non-small cell lung cancer (NSCLC), since the introduction of first line cancer drugs nearly 30 years ago."
According to Dr Modi, this drug can be used along with other cancer medication and trials on this drug has proved that it can boost median survival by over 40% in patients suffering from squamous NSCLC.
"It has taken us over a decade, a huge investment and a dedicated research and development team to develop this unique drug. We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years," Modi said.